Complex role of nicotinamide adenine dinucleotide in the regulation of programmed cell death pathways

Biochemical Pharmacology

Volumn 101, Issue , 2016, Pages 13-26

  Preyat, Nicolas ^a   Leo, Oberdan ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Apoptosis; NAD; NAMPT; Necroptosis; Parthanatos; Regulated cell death

Indexed keywords

HYDROGEN PEROXIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; SIRTUIN; SPHINGOLIPID; NEW DRUG;

APOPTOSIS; ARTICLE; AUTOPHAGY; BIOLOGICAL FUNCTIONS; CANCER THERAPY; CELL DEATH; CELL LEVEL; CELL METABOLISM; CELL SURVIVAL; CELL VIABILITY; DNA DAMAGE; DRUG TARGETING; ENERGY TRANSFER; ENZYME METABOLISM; HUMAN; METABOLIC STRESS; METABOLITE; NECROPTOSIS; NECROSIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PYROPTOSIS; WALLERIAN DEGENERATION; ANIMAL; BIOLOGICAL MODEL; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; PHYSIOLOGY;

ANIMALS; APOPTOSIS; AUTOPHAGY; DRUG DISCOVERY; DRUGS, INVESTIGATIONAL; HUMANS; MODELS, BIOLOGICAL; NAD; NECROSIS;

EID: 84957443041     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2015.08.110     Document Type: Note

References (200)

1. R.A. Lockshin, and C.M. Williams Programmed cell death - II. Endocrine potentiation of the breakdown of the intersegmental muscles of silkmoths J. Insect Physiol. 10 1964 643 649
2. J.F. Kerr, A.H. Wyllie, and A.R. Currie Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics Br. J. Cancer 26 1972 239 257
3. H.M. Ellis, and H.R. Horvitz Genetic control of programmed cell death in the nematode C. elegans Cell 44 1986 817 829
4. F.K.-M. Chan, J. Shisler, J.G. Bixby, M. Felices, L. Zheng, M. Appel, and et al. A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses J. Biol. Chem. 278 2003 51613 51621
5. A. Degterev, Z. Huang, M. Boyce, Y. Li, P. Jagtap, N. Mizushima, and et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury Nat. Chem. Biol. 1 2005 112 119
6. L. Galluzzi, I. Vitale, J.M. Abrams, E.S. Alnemri, E.H. Baehrecke, M.V. Blagosklonny, and et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012 Cell Death Differ. 19 2012 107 120
7. L. Galluzzi, P. Bravo-San, J.M. edro, I. Vitale, S.A. Aaronson, J.M. Abrams, D. Adam, and et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015 Cell Death Differ. 22 2015 58 73
8. A. Degterev, and J. Yuan Expansion and evolution of cell death programmes Nat. Rev. Mol. Cell Biol. 9 2008 378 390
9. T.I. Gossmann, M. Ziegler, P. Puntervoll, L.F. de Figueiredo, S. Schuster, and I. Heiland NAD(+) biosynthesis and salvage - a phylogenetic perspective FEBS J. 279 2012 3355 3363
10. F. Koch-Nolte, S. Fischer, F. Haag, and M. Ziegler Compartmentation of NAD(+)-dependent signalling FEBS Lett. 585 2011 1651 1656
11. A. Nikiforov, C. Dölle, M. Niere, and M. Ziegler Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation J. Biol. Chem. 286 2011 21767 21778
12. N. Preyat, and O. Leo Sirtuin deacylases: a molecular link between metabolism and immunity J. Leukocyte Biol. 93 2013 669 680
13. A. Rongvaux, R.J. Shea, M.H. Mulks, D. Gigot, J. Urbain, O. Leo, and et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis Eur. J. Immunol. 32 2002 3225 3234
14. S.-I. Imai The NAD. World: a new systemic regulatory network for metabolism and aging - Sirt1, systemic NAD biosynthesis, and their importance Cell Biochem. Biophys. 53 2009 65 74
15. J.R. Revollo, A. Körner, K.F. Mills, A. Satoh, T. Wang, A. Garten, and et al. Nampt/PBEF/visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme Cell Metab. 6 2007 363 375
16. A. Rongvaux, M. Galli, S. Denanglaire, G. Van, F. ool, P.L. Drèze, C. Szpirer, and et al. Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress J. Immunol. 181 2008 4685 4695
17. M. Fulco, Y. Cen, P. Zhao, E.P. Hoffman, M.W. McBurney, A.A. Sauve, and et al. Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt Dev. Cell. 14 2008 661 673
18. H. Yang, T. Yang, J.A. Baur, E. Perez, T. Matsui, J.J. Carmona, and et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival Cell 130 2007 1095 1107
19. T. Nakagawa, D.J. Lomb, M.C. Haigis, and L. Guarente SIRT5 deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle Cell 137 2009 560 570
20. S.-K. Bae, S.-R. Kim, J.G. Kim, J.Y. Kim, T.H. Koo, H.-O. Jang, and et al. Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1 FEBS Lett. 580 2006 4105 4113
21. K. Segawa, A. Fukuhara, N. Hosogai, K. Morita, Y. Okuno, M. Tanaka, and et al. Visfatin in adipocytes is upregulated by hypoxia through HIF1alpha-dependent mechanism Biochem. Biophys. Res. Commun. 349 2006 875 882
22. L. Frydelund-Larsen, T. Akerstrom, S. Nielsen, P. Keller, C. Keller, and B.K. Pedersen Visfatin mRNA expression in human subcutaneous adipose tissue is regulated by exercise Am. J. Physiol. Endocrinol. Metab. 292 2007 E24 E31
23. S. Kralisch, J. Klein, U. Lossner, M. Bluher, R. Paschke, M. Stumvoll, and et al. Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes J. Endocrinol. 185 2005 R1 R8
24. T. Finkel, C.-X. Deng, and R. Mostoslavsky Recent progress in the biology and physiology of sirtuins Nature 460 2009 587 591
25. N. Preyat, M. Rossi, J. Kers, L. Chen, J. Bertin, P.J. Gough, and et al. Intracellular nicotinamide adenine dinucleotide promotes TNF-induced necroptosis in a sirtuin-dependent manner Cell Death Differ. 2015 10.1038/cdd.2015.60
26. N. Preyat, and O. Leo Reassessing the role of NAD as a pro-survival factor Mol. Cell. Oncol. 2015 10.1080/23723556.2015.1062591
27. S.-Y. Jang, H.T. Kang, and E.S. Hwang Nicotinamide-induced mitophagy: event mediated by high NAD+/NADH ratio and SIRT1 protein activation J. Biol. Chem. 287 2012 19304 19314
28. P. Wang, Y.-F. Guan, H. Du, Q.-W. Zhai, D.-F. Su, and C.-Y. Miao Induction of autophagy contributes to the neuroprotection of nicotinamide phosphoribosyltransferase in cerebral ischemia Autophagy 8 2012 77 87
29. C. Zheng, J. Han, W. Xia, S. Shi, J. Liu, and W. Ying NAD+ administration decreases ischemic brain damage partially by blocking autophagy in a mouse model of brain ischemia Neurosci. Lett. 512 2012 67 71
30. Y. Liu, and B. Levine Autosis and autophagic cell death: the dark side of autophagy Cell Death Differ. 22 2014 367 376
31. L. Lin, and E.H. Baehrecke Autophagy cell death and cancer Mol. Cell. Oncol. 2 2015 e985913 10.4161/23723556.2014.985913
32. I.H. Lee, L. Cao, R. Mostoslavsky, D.B. Lombard, J. Liu, N.E. Bruns, and et al. A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy Proc. Natl. Acad. Sci. U. S. A. 105 2008 3374 3379
33. R. Huang, Y. Xu, W. Wan, X. Shou, J. Qian, Z. You, and et al. Deacetylation of nuclear LC3 drives autophagy initiation under starvation Mol. Cell 57 2015 456 466
34. E. Morselli, M.C. Maiuri, M. Markaki, E. Megalou, A. Pasparaki, K. Palikaras, and et al. Caloric restriction and resveratrol promote longevity through the sirtuin - dependent induction of autophagy Cell Death Dis. 1 2010 e10
35. T. Sun, X. Li, P. Zhang, W.-D. Chen, H. Zhang, D.-D. Li, and et al. Acetylation of beclin 1 inhibits autophagosome maturation and promotes tumour growth Nat. Commun. 6 2015 7215
36. R.A. Billington, A.A. Genazzani, C. Travelli, and F. Condorelli NAD depletion by FK866 induces autophagy Autophagy 4 2008 385 387
37. J.A. Muñoz-Gámez, J.M. Rodríguez-Vargas, R. Quiles-Pérez, R. Aguilar-Quesada, D. Martín-Oliva, M. de, G. urcia, and et al. PARP-1 is involved in autophagy induced by DNA damage Autophagy 5 2009 61 74
38. L. Polletta, E. Vernucci, I. Carnevale, T. Arcangeli, D. Rotili, S. Palmerio, and et al. SIRT5 regulation of ammonia-induced autophagy and mitophagy Autophagy 11 2015 253 270
39. C.-P. Hsu, S. Oka, D. Shao, N. Hariharan, and J. Sadoshima Nicotinamide phosphoribosyltransferase regulates cell survival through NAD+ synthesis in cardiac myocytes Circ. Res. 105 2009 481 491
40. P. Wang, T.-Y. Xu, Y.-F. Guan, W.-W. Tian, B. Viollet, Y.-C. Rui, and et al. Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway Ann. Neurol. 69 2011 360 374
41. S. Magnifico, L. Saias, B. Deleglise, E. Duplus, D. Kilinc, M.-C. Miquel, and et al. NAD+ acts on mitochondrial SirT3 to prevent axonal caspase activation and axonal degeneration FASEB J. 27 2013 4712 4722
42. W. Wang, C. Yan, J. Zhang, R. Lin, Q. Lin, L. Yang, and et al. SIRT1 inhibits TNF-α-induced apoptosis of vascular adventitial fibroblasts partly through the deacetylation of FoxO1 Apoptosis 18 2013 689 701
43. Y. Cheng, X. Ren, A.S. Gowda, Y. Shan, L. Zhang, Y.-S. Yuan, and et al. Interaction of Sirt3 with OGG1 contributes to repair of mitochondrial DNA and protects from apoptotic cell death under oxidative stress Cell Death Dis. 4 2013 e731
44. M. Pittelli, L. Cavone, A. Lapucci, C. Oteri, R. Felici, E. Niccolai, and et al. Nicotinamide phosphoribosyltransferase (NAMPT) activity is essential for survival of resting lymphocytes Immunol. Cell Biol. 92 2014 191 199
45. S.H. Jia, Y. Li, J. Parodo, A. Kapus, L. Fan, O.D. Rotstein, and et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis J. Clin. Invest. 113 2004 1380
46. L. Moreno-Vinasco, H. Quijada, S. Sammani, J. Siegler, E. Letsiou, R. Deaton, and et al. Nicotinamide phosphoribosyltransferase inhibitor is a novel therapeutic candidate in murine models of inflammatory lung injury Am. J. Respir. Cell Mol. Biol. 51 2014 223 228
47. S.H. Jia, Y. Li, J. Parodo, A. Kapus, L. Fan, O.D. Rotstein, and et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis J. Clin. Invest. 113 2004 1318 1327
48. J.D. West, C. Ji, and L.J. Marnett Modulation of DNA fragmentation factor 40 nuclease activity by poly(ADP-ribose) polymerase-1 J. Biol. Chem. 280 2005 15141 15147
49. I.M.M. Van Leeuwen, M. Higgins, J. Campbell, A.R. McCarthy, M.C.C. Sachweh, A.M. Navarro, and et al. Modulation of p53C-Terminal Acetylation by mdm2, p14ARF, and Cytoplasmic SirT2 Mol. Cancer Ther. 12 2013 471 480
50. S. Gonfloni, V. Iannizzotto, E. Maiani, G. Bellusci, S. Ciccone, and M. Diederich P53 and Sirt1: routes of metabolism and genome stability Biochem. Pharmacol. 92 2014 149 156
51. J. Zhang, L. Shen, and L. Sun The regulation of radiosensitivity by p53 and its acetylation Cancer Lett. 363 2015 108 118
52. L. Li, L. Wang, L. Li, Z. Wang, Y. Ho, T. McDonald, and et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib Cancer Cell 21 2012 266 281
53. Q. Zhang, S.X. Zeng, Y. Zhang, Y. Zhang, D. Ding, Q. Ye, and et al. A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53 EMBO Mol. Med. 4 2012 298 312
54. B.K. Thakur, T. Dittrich, P. Chandra, A. Becker, Y. Lippka, D. Selvakumar, and et al. Inhibition of NAMPT pathway by FK866 activates the function of p53 in HEK293T cells Biochem. Biophys. Res. Commun. 424 2012 371 377
55. B.K. Thakur, T. Dittrich, P. Chandra, A. Becker, W. Kuehnau, J.-H. Klusmann, and et al. Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells Int. J. Cancer 132 2013 766 774
56. A.V. Hafner, J. Dai, A.P. Gomes, C.-Y. Xiao, C.M. Palmeira, A. Rosenzweig, and et al. Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy Aging (Albany, NY) 2 2010 914 923
57. L. Pellegrini, B. Pucci, L. Villanova, M.L. Marino, G. Marfe, L. Sansone, and et al. SIRT3 protects from hypoxia and staurosporine-mediated cell death by maintaining mitochondrial membrane potential and intracellular pH Cell Death Differ. 19 2012 1815 1825
58. F. Yeung, J.E. Hoberg, C.S. Ramsey, M.D. Keller, D.R. Jones, R.A. Frye, and et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase EMBO J. 23 2004 2369 2380
59. K. Takayama, K. Ishida, T. Matsushita, N. Fujita, S. Hayashi, K. Sasaki, and et al. SIRT1 regulation of apoptosis of human chondrocytes Arthritis Rheumatol. 60 2009 2731 2740
60. O. Gabay, H. Oppenhiemer, H. Meir, K. Zaal, C. Sanchez, and M. Dvir-Ginzberg Increased apoptotic chondrocytes in articular cartilage from adult heterozygous SirT1 mice Ann. Rheum Dis. 71 2012 613 616
61. K.M. Rothgiesser, S. Erener, S. Waibel, B. Lüscher, and M.O. Hottiger SIRT2 regulates NF-κB dependent gene expression through deacetylation of p65 Lys310 J. Cell Sci. 123 2010 4251 4258
62. T.F. Pais, Szego M, O. Marques, L. Miller-Fleming, P. Antas, P. Guerreiro, and et al. The NAD-dependent deacetylase sirtuin 2 is a suppressor of microglial activation and brain inflammation EMBO J. 32 2013 2603 2616
63. J. Zhang, V.L. Dawson, T.M. Dawson, and S.H. Snyder Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity Science 263 1994 687 689
64. M.J. Eliasson, K. Sampei, A.S. Mandir, P.D. Hurn, R.J. Traystman, J. Bao, and et al. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia Nat. Med. 3 1997 1089 1095
65. S. Love Oxidative stress in brain ischemia Brain Pathol. 9 1999 119 131
66. A. Peralta-Leal, J.M. Rodríguez-Vargas, R. Aguilar-Quesada, M.I. Rodríguez, J.L. Linares, A. de, M.R. lmodovar, and et al. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases Free Radical Biol. Med. 47 2009 13 26
67. M.Y. Kim, T. Zhang, and W.L. Kraus Poly(ADP-ribosyl) ation by PARP-1: PAR-laying NAD+ into a nuclear signal Genes Dev. 19 2005 1951 1967
68. W. Ying, C.C. Alano, P. Garnier, and R.A. Swanson NAD+ as a metabolic link between DNA damage and cell death J. Neurosci. Res. 79 2005 216 223
69. J.B. Pillai, A. Isbatan, S. Imai, and M.P. Gupta Poly(ADP-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity J. Biol. Chem. 280 2005 43121 43130
70. W.-X. Zong, D. Ditsworth, D.E. Bauer, Z.-Q. Wang, and C.B. Thompson Alkylating DNA damage stimulates a regulated form of necrotic cell death Genes Dev. 18 2004 1272 1282
71. S.-W. Yu, H. Wang, M.F. Poitras, C. Coombs, W.J. Bowers, H.J. Federoff, and et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor Science 297 2002 259 263
72. S.-W. Yu, S.A. Andrabi, H. Wang, N.S. Kim, G.G. Poirier, T.M. Dawson, and et al. Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death Proc. Natl. Acad. Sci. U. S. A. 103 2006 18314 18319
73. S.A. Andrabi, N.S. Kim, S.-W. Yu, H. Wang, D.W. Koh, M. Sasaki, and et al. Poly(ADP-ribose) (PAR) polymer is a death signal Proc Natl Acad Sci USA. 103 2006 18308 18313
74. C. Artus, H. Boujrad, A. Bouharrour, M.-N. Brunelle, S. Hoos, V.J. Yuste, and et al. AIF promotes chromatinolysis and caspase-independent programmed necrosis by interacting with histone H2AX EMBO J. 29 2010 1585 1599
75. L. Formentini, A. Macchiarulo, G. Cipriani, E. Camaioni, E. Rapizzi, R. Pellicciari, and et al. Poly(ADP-ribose) catabolism triggers AMP-dependent mitochondrial energy failure J. Biol. Chem. 284 2009 17668 17676
76. S.A. Andrabi, G.K.E. Umanah, C. Chang, D.A. Stevens, S.S. Karuppagounder, J.-P. Gagné, and et al. Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis Proc. Natl. Acad. Sci. U. S. A. 111 2014 10209 10214
77. S. Goto, R. Xue, N. Sugo, M. Sawada, K.K. Blizzard, M.F. Poitras, and et al. Poly(ADP-ribose) polymerase impairs early and long-term experimental stroke recovery Stroke 33 2002 1101 1106
78. W. Paschen, L. Oláh, and G. Mies Effect of transient focal ischemia of mouse brain on energy state and NAD levels: no evidence that NAD depletion plays a major role in secondary disturbances of energy metabolism J. Neurochem. 75 2000 1675 1680
79. A.L. Perraud, A. Fleig, C.A. Dunn, L.A. Bagley, P. Launay, C. Schmitz, and et al. ADP-ribose gating of the calcium-permeable LTRPC2 channel revealed by Nudix motif homology Nature 411 2001 595 599
80. B. Buelow, Y. Song, and A.M. Scharenberg The poly(ADP-ribose) polymerase PARP-1 is required for oxidative stress-induced TRPM2 activation in lymphocytes J. Biol. Chem. 283 2008 24571 24583
81. C. Blenn, P. Wyrsch, J. Bader, M. Bollhalder, and F.R. Althaus Poly(ADP-ribose) glycohydrolase is an upstream regulator of Ca2+ fluxes in oxidative cell death Cell. Mol. Life Sci. 68 2011 1455 1466
82. D.L. Douglas, and C.P. Baines PARP1-mediated necrosis is dependent on parallel JNK and Ca2+/calpain pathways J. Cell Sci. 127 2014 4134 4145
83. C.C. Alano, W. Ying, and R.A. Swanson Poly(ADP-ribose) polymerase-1-mediated cell death in astrocytes requires NAD+ depletion and mitochondrial permeability transition J. Biol. Chem. 279 2004 18895 18902
84. K. Zhu, R.A. Swanson, and W. Ying NADH can enter into astrocytes and block poly(ADP-ribose) polymerase-1-mediated astrocyte death Neuroreport 16 2005 1209 1212
85. Y. Zhao, Y.-F. Guan, X.-M. Zhou, G.-Q. Li, Z.-Y. Li, C.-C. Zhou, and et al. Regenerative neurogenesis after ischemic stroke promoted by nicotinamide phosphoribosyltransferase-nicotinamide adenine dinucleotide cascade Stroke 46 2015 1966 1974
86. S.H. Kim, H.F. Lu, and C.C. Alano Neuronal Sirt3 protects against excitotoxic injury in mouse cortical neuron culture PLoS One 6 2011 e14731
87. A. Sistigu, G. Manic, F. Obrist, and I. Vitale Trial watch: inhibiting PARP enzymes for anticancer therapy Mol. Cell. Oncol. 2015 10.1080/23723556.2015.1053594
88. J.M. De Murcia, C. Niedergang, C. Trucco, M. Ricoul, B. Dutrillaux, M. Mark, and et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells Proc. Natl. Acad. Sci. U. S. A. 94 1997 7303 7307
89. C.A. Delaney, L.Z. Wang, S. Kyle, A.W. White, A.H. Calvert, N.J. Curtin, and et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines Clin. Cancer Res. 6 2000 2860 2867
90. M. Malanga, and F.R. Althaus Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and Induces DNA. Strand break resealing J. Biol. Chem. 279 2004 5244 5248
91. P.C. Fong, D.S. Boss, T.A. Yap, A. Tutt, P. Wu, M. Mergui-Roelvink, and et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N. Engl. J. Med. 361 2009 123 134
92. H. Farmer, N. McCabe, C.J. Lord, A.N.J. Tutt, D.A. Johnson, T.B. Richardson, and et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 2005 917 921
93. I. Bajrami, A. Kigozi, W. Van, A. everwijk, R. Brough, J. Frankum, C.J. Lord, and et al. Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells EMBO Mol. Med. 4 2012 1087 1096
94. K. Yuan, Y. Sun, T. Zhou, J. McDonald, and Y. Chen PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy Clin. Cancer Res. 19 2013 4750 4759
95. X.W. Meng, B.D. Koh, J. Zhang, K.S. Flatten, P.A. Schneider, D.D. Billadeau, and et al. Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression J. Biol. Chem. 289 2014 20543 20558
96. D. Tang, R. Kang, K.M. Livesey, C.-W. Cheh, A. Farkas, P. Loughran, and et al. Endogenous HMGB1 regulates autophagy J. Cell Biol. 190 2010 881 892
97. M. Yang, L. Liu, M. Xie, X. Sun, Y. Yu, R. Kang, and et al. Poly-ADP-ribosylation of HMGB1 regulates TNFSF10/TRAIL resistance through autophagy Autophagy 11 2015 214 224
98. Y.S. Cho, S. Challa, D. Moquin, R. Genga, T.D. Ray, M. Guildford, and et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation Cell 137 2009 1112 1123
99. M. Lamkanfi, and V.M. Dixit Manipulation of host cell death pathways during microbial infections Cell Host Microbe 8 2010 44 54
100. A. Kaczmarek, P. Vandenabeele, and D.V. Krysko Necroptosis: the release of damage-associated molecular patterns and its physiological relevance Immunity 38 2013 209 223
101. D. Wallach, T. Kang, S. Yang, and A. Kovalenko The in vivo significance of necroptosis: lessons from exploration of caspase-8 function Cytokine Growth Factor Rev. 25 2014 157 165
102. M. Pasparakis, and P. Vandenabeele Necroptosis and its role in inflammation Nature 517 2015 311 320
103. N. Narayan, I.H. Lee, R. Borenstein, J. Sun, R. Wong, G. Tong, and et al. The NAD-dependent deacetylase SIRT2 is required for programmed necrosis Nature 492 2012 199 204
104. K. Newton, J.M. Hildebrand, Z. Shen, D. Rodriguez, S. Alvarez-Diaz, S. Petersen, and et al. Is SIRT2 required for necroptosis? Nature 506 2014 E4 E6
105. L. Yuan, Z. Wang, L. Liu, and X. Jian Inhibiting histone deacetylase 6 partly protects cultured rat cortical neurons from oxygen-glucose deprivation-induced necroptosis Mol. Med. Rep. 12 2015 2661 2667
106. T.F. Outeiro, E. Kontopoulos, S.M. Altmann, I. Kufareva, K.E. Strathearn, A.M. Amore, and et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease Science 317 2007 516 519
107. R. Luthi-Carter, D.M. Taylor, J. Pallos, E. Lambert, A. Amore, A. Parker, and et al. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis Proc. Natl. Acad. Sci. U. S. A. 107 2010 7927 7932
108. V. Chopra, L. Quinti, J. Kim, L. Vollor, K.L. Narayanan, C. Edgerly, and et al. The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models Cell Rep. 2 2012 1492 1497
109. J. Li, T. McQuade, A.B. Siemer, J. Napetschnig, K. Moriwaki, Y. Hsiao, and et al. The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis Cell 150 2012 339 350
110. T.G. Mack, M. Reiner, B. Beirowski, W. Mi, M. Emanuelli, D. Wagner, and et al. Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene Nat. Neurosci. 4 2001 1199 1206
111. J. Wang, Q. Zhai, Y. Chen, E. Lin, W. Gu, M.W. McBurney, and et al. A local mechanism mediates NAD-dependent protection of axon degeneration J. Cell Biol. 170 2005 349 355
112. J. Gilley, and M.P. Coleman Endogenous Nmnat2 is an essential survival factor for maintenance of healthy axons PLoS Biol. 8 2010 85
113. S. Di, M. tefano, I. Nascimento-Ferreira, G. Orsomando, V. Mori, J. Gilley, R. Brown, and et al. A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration Cell Death Differ. 22 2014 731 742
114. + destruction Science 348 2015 453 457
115. T. Araki, Y. Sasaki, and J. Milbrandt Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration Science 305 2004 1010 1013
116. N.R. Sundaresan, M. Gupta, G. Kim, S.B. Rajamohan, A. Isbatan, and M.P. Gupta Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice J. Clin. Invest. 119 2009 2758 2771
117. A. Brunet, L.B. Sweeney, J.F. Sturgill, K.F. Chua, P.L. Greer, Y. Lin, and et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase Science 303 2004 2011 2015
118. K.G. Cheung, L.K. Cole, B. Xiang, K. Chen, X. Ma, Y. Myal, and et al. Sirtuin-3 (SIRT3) protein attenuates doxorubicin-induced oxidative stress and improves mitochondrial respiration in H9c2 cardiomyocytes J. Biol. Chem. 290 2015 10981 10993
119. L. Liu, C. Peritore, J. Ginsberg, M. Kayhan, and G. Donmez SIRT3 attenuates MPTP-induced nigrostriatal degeneration via enhancing mitochondrial antioxidant capacity Neurochem. Res. 40 2015 600 608
120. T. Chen, J. Liu, N. Li, S. Wang, H. Liu, J. Li, and et al. Mouse SIRT3 attenuates hypertrophy-related lipid accumulation in the heart through the deacetylation of LCAD PLoS One 10 2015 e0118909
121. G. Liu, M. Cao, Y. Xu, and Y. Li SIRT3 protects endothelial cells from high glucose-induced cytotoxicity Int. J. Clin. Exp. Pathol. 8 2015 353 360
122. J. Yin, P. Han, Z. Tang, Q. Liu, and J. Shi Sirtuin 3 mediates neuroprotection of ketones against ischemic stroke J. Cereb. Blood Flow Metab. 2015 1 7 10.1038/jcbfm.2015.123
123. Y. Quan, L. Xia, J. Shao, S. Yin, C.Y. Cheng, W. Xia, and et al. Adjudin protects rodent cochlear hair cells against gentamicin ototoxicity via the SIRT3-ROS pathway Sci. Rep. 5 2015 8181
124. D. Guan, J.H. Lim, L. Peng, Y. Liu, M. Lam, E. Seto, and et al. Deacetylation of the tumor suppressor protein PML regulates hydrogen peroxide-induced cell death Cell Death Dis. 5 2014 e1340
125. C. Gurrieri, P. Capodieci, R. Bernardi, P.P. Scaglioni, K. Nafa, L.J. Rush, and et al. Loss of the tumor suppressor PML in human cancers of multiple histologic origins J. Natl. Cancer Inst. 96 2004 269 279
126. T. Misawa, M. Takahama, T. Kozaki, H. Lee, J. Zou, T. Saitoh, and et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome Nat. Immunol. 14 2013 454 460
127. K. Novak, R. ujundzić, N. Žarković, T. Gall, and K. roselj Pyridine nucleotides in regulation of cell death and survival by redox and non-redox reactions Crit. Rev. Eukaryot. Gene Exp. 24 2014 287 309
128. K. Czubowicz, and R. Strosznajder Ceramide in the molecular mechanisms of neuronal cell death. The role of sphingosine-1-phosphate Mol. Neurobiol. 50 2014 26 37
129. M. Rahman, N.K. Nirala, A. Singh, L.J. Zhu, K. Taguchi, T. Bamba, and et al. Drosophila Sirt2/mammalian SIRT3 deacetylates ATP synthase β and regulates complex V activity J. Cell Biol. 206 2014 289 305
130. M. Figuera-Losada, M. Stathis, J.M. Dorskind, A.G. Thomas, V.V.R. Bandaru, S.-W. Yoo, and et al. Cambinol, a novel inhibitor of neutral sphingomyelinase 2 shows neuroprotective properties PLoS One 10 2015 e0124481
131. N. Del, C. agro, Y. Xiao, L. Rangell, M. Reichelt, and T. O'Brien Depletion of the central metabolite NAD leads to oncosis-mediated cell death J. Biol. Chem. 289 2014 35182 35192
132. Van, V. der, E. eer, C. Ho, C. O'Neil, N. Barbosa, R. Scott, S.P. Cregan, and et al. Extension of human cell lifespan by nicotinamide phosphoribosyltransferase J. Biol. Chem. 282 2007 10841 10845
133. M.A.A. Koike Folgueira Gene expression profile associated with response to doxorubicin-based therapy in breast cancer Clin. Cancer Res. 11 2005 7434 7443
134. T.Q. Bi, X.M. Che, X.H. Liao, D.J. Zhang, H.L. Long, H.J. Li, and et al. Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil Oncol. Rep. 26 2011 1251 1257
135. B. Wang, M.K. Hasan, E. Alvarado, H. Yuan, H. Wu, and W.Y. Chen NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response Oncogene 30 2011 907 921
136. K. Wosikowski, K. Mattern, I. Schemainda, M. Hasmann, B. Rattel, and R. Löser WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells Cancer Res. 62 2002 1057 1062
137. J. Drevs, R. Löser, B. Rattel, and N. Esser Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma Anticancer Res. 23 2003 4853 4858
138. A. Nahimana, A. Attinger, D. Aubry, P. Greaney, C. Ireson, A.V. Thougaard, and et al. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies Blood 113 2009 3276 3286
139. H. Yang, M. Yen, C.-C. Lin, C. Lin, Y. Chen, T. Weng, and et al. A combination of the metabolic enzyme inhibitor APO866 and the immune adjuvant l-1-methyl tryptophan induces additive antitumor activity Exp. Biol. Med. (Maywood) 235 2010 869 876
140. A. Le, C.R. Cooper, A.M. Gouw, R. Dinavahi, A. Maitra, L.M. Deck, and et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression Proc. Natl. Acad. Sci. 107 2010 2037 2042
141. M. Muruganandham, A.A. Alfieri, C. Matei, Y. Chen, G. Sukenick, I. Schemainda, and et al. Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy Clin. Cancer Res. 11 2005 3503 3513
142. P. Beauparlant, D. Bédard, C. Bernier, H. Chan, K. Gilbert, D. Goulet, and et al. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777 Anticancer Drugs 20 2009 346 354
143. M. Watson, A. Roulston, L. Bélec, X. Billot, R. Marcellus, D. Bédard, and et al. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors Mol. Cell Biol. 29 2009 5872 5888
144. U.H. Olesen, A.V. Thougaard, P.B. Jensen, and M. Sehested A Preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor Mol. Cancer Ther. 9 2010 1609 1617
145. A. Roulston, and G.C. Shore New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncology Mol. Cell. Oncol. 2015 10.1080/23723556.2015.1052180
146. E. Binderup, F. Björkling, P.V. Hjarnaa, S. Latini, B. Baltzer, M. Carlsen, and et al. EB1627: a soluble prodrug of the potent anticancer cyanoguanidine CHS828 Bioorg. Med. Chem. Lett. 15 2005 2491 2494
147. U. Galli, C. Travelli, A. Massarotti, G. Fakhfouri, R. Rahimian, G.C. Tron, and et al. Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors J. Med. Chem. 56 2013 6279 6296
148. D. Sampath, T.S. Zabka, D.L. Misner, T. O'Brien, and P.S. Dragovich Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer Pharmacol. Ther. 151 2015 16 31
149. H. Van, R. orssen, M. Willemse, A. Haeger, F. Attanasio, T. Güneri, A. Schwab, and et al. Intracellular NAD(H) levels control motility and invasion of glioma cells Cell. Mol. Life Sci. 70 2013 2175 2190
150. R. Pandithage, R. Lilischkis, K. Harting, A. Wolf, B. Jedamzik, J. Lüscher-Firzlaff, and et al. The regulation of SIRT2 function by cyclin-dependent kinases affects cell motility J. Cell Biol. 180 2008 915 929
151. H. Yin, van, V. der, E. eer, M.J. Frontini, V. Thibert, C. O'Neil, A. Watson, and et al. Intrinsic directionality of migrating vascular smooth muscle cells is regulated by NAD+ biosynthesis J. Cell Sci. 125 2012 5770 5780
152. A.F. Santidrian, S.E. LeBoeuf, E.D. Wold, M. Ritland, J.S. Forsyth, and B.H. Felding Nicotinamide phosphoribosyltransferase can affect metastatic activity and cell adhesive functions by regulating integrins in breast cancer DNA Repair (Amst) 23 2014 79 87
153. A.F. Santidrian, A. Matsuno-Yagi, M. Ritland, B.B. Seo, S.E. LeBoeuf, L.J. Gay, and et al. Mitochondrial complex I activity and NAD+/NADH balance regulate breast cancer progression J. Clin. Invest. 123 2013 1068 1081
154. S. Bruzzone, F. Fruscione, S. Morando, T. Ferrando, A. Poggi, A. Garuti, and et al. Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE PLoS One 4 2009 e7897
155. P. Aksoy, C. Escande, T.A. White, M. Thompson, S. Soares, J.C. Benech, and et al. Regulation of SIRT 1 mediated NAD dependent deacetylation: a novel role for the multifunctional enzyme CD38 Biochem. Biophys. Res. Commun. 349 2006 353 359
156. Y. Ge, W. Jiang, L. Gan, L. Wang, C. Sun, P. Ni, and et al. Mouse embryonic fibroblasts from CD38 knockout mice are resistant to oxidative stresses through inhibition of reactive oxygen species production and Ca2+ overload Biochem. Biophys. Res. Commun. 399 2010 167 172
157. L. Mayo, J. Jacob-Hirsch, N. Amariglio, G. Rechavi, M.-J. Moutin, F.E. Lund, and et al. Dual role of CD38 in microglial activation and activation-induced cell death J. Immunol. 181 2008 92 103
158. Y. Ma, J. Jiang, L. Wang, H. Nie, W. Xia, J. Liu, and et al. CD38 is a key enzyme for the survival of mouse microglial BV2 cells Biochem. Biophys. Res. Commun. 418 2012 714 719
159. Z.-F. Song, X.-P. Ji, X.-X. Li, S.-J. Wang, and S.-H. Wang Inhibition of the activity of poly(ADP-ribose) polymerase reduces heart ischaemia/reperfusion injury via suppressing JNK-mediated AIF translocation J. Cell. Mol. Med. 12 2008 1220 1228
160. T.M. Kauppinen, S.W. Suh, A.E. Berman, A.M. Hamby, and R.A. Swanson Inhibition of poly(ADP-ribose) polymerase suppresses inflammation and promotes recovery after ischemic injury J. Cereb. Blood Flow Metab. 29 2009 820 829
161. D. Liu, R. Gharavi, M. Pitta, M. Gleichmann, and M.P. Mattson Nicotinamide prevents NAD+ depletion and protects neurons against excitotoxicity and cerebral ischemia: NAD+ consumption by SIRT1 may endanger energetically compromised neurons Neuromol. Med. 11 2009 28 42
162. D.W. Koh, T.M. Dawson, and V.L. Dawson Mediation of cell death by poly(ADP-ribose) polymerase-1 Pharmacol. Res. 52 2005 5 14
163. H. Mota-Filipe, B. Sepodes, M.C. McDonald, S. Cuzzocrea, R. Pinto, and C. Thiemermann The novel PARP inhibitor 5-aminoisoquinolinone reduces the liver injury caused by ischemia and reperfusion in the rat Med. Sci. Monit. 8 2002 BR444 R453
164. G. Lenzsér, B. Kis, J.A. Snipes, T. Gáspár, P. Sándor, K. Komjáti, and et al. Contribution of poly(ADP-ribose) polymerase to postischemic blood-brain barrier damage in rats J. Cereb. Blood Flow Metab. 27 2007 1318 1326
165. R.K. Kaundal, K.K. Shah, and S.S. Sharma Neuroprotective effects of NU1025, a PARP inhibitor in cerebral ischemia are mediated through reduction in NAD depletion and DNA fragmentation Life Sci. 79 2006 2293 2302
166. N.J. Curtin, and C. Szabo Therapeutic applications of PARP inhibitors: anticancer therapy and beyond Mol. Aspects Med. 34 2013 1217 1256
167. T. Nagayama, R.P. Simon, D. Chen, D.C. Henshall, W. Pei, R.A. Stetler, and et al. Activation of poly(ADP-ribose) polymerase in the rat hippocampus may contribute to cellular recovery following sublethal transient global ischemia J. Neurochem. 74 2002 1636 1645
168. D. D'amours, S. Desnoyers, I. D'silva, and G.G. Poirier Poly(ADP-ribosyl) ation reactions in the regulation of nuclear functions Biochem. J. 342 1999 249
169. C.C. Alano, A. Tran, R. Tao, W. Ying, J.S. Karliner, and R.A. Swanson Differences among cell types in NAD(+) compartmentalization: a comparison of neurons, astrocytes, and cardiac myocytes J. Neurosci. Res. 85 2007 3378 3385
170. S.J. Won, B.Y. Choi, B.H. Yoo, M. Sohn, W. Ying, R.A. Swanson, and et al. Prevention of traumatic brain injury-induced neuron death by intranasal delivery of nicotinamide adenine dinucleotide J. Neurotrauma 29 2012 1401 1409
171. Z.X. Liu, O. Azhipa, S. Okamoto, S. Govindarajan, and G. Dennert Extracellular nicotinamide adenine dinucleotide induces t cell apoptosis in vivo and in vitro J. Immunol. 167 2001 4942 4947
172. M. Seman, S. Adriouch, F. Scheuplein, C. Krebs, D. Freese, G. Glowacki, and et al. NAD-induced T cell death: ADP-ribosylation of cell surface proteins by ART2 activates the cytolytic P2X7 purinoceptor Immunity 19 2003 571 582
173. B. Rissiek, F. Haag, O. Boyer, F. Koch-Nolte, and S. Adriouch ADP-ribosylation of P2X72: a matter of life and death for regulatory T cells and natural killer T cells Curr. Top. Microbiol. Immunol. 351 2014 107 126
174. F. Haag, F. Koch-Nolte, M. Kühl, S. Lorenzen, and H.-G. Thiele Premature stop codons inactivate the RT6 genes of the human and chimpanzee species J. Mol. Biol. 243 1994 537 546
175. A. Nikiforov, V. Kulikova, and M. Ziegler The human NAD metabolome: functions, metabolism and compartmentalization Crit. Rev. Biochem. Mol. Biol. 2015 1 10.3109/10409238.2015.1028612
176. J. Skokowa, D. Lan, B.K. Thakur, F. Wang, K. Gupta, G. Cario, and et al. NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway Nat. Med. 15 2009 151 158
177. K.J. Bitterman, R.M. Anderson, H.Y. Cohen, M. Latorre-Esteves, and D.A. Sinclair Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1 J. Biol. Chem. 277 2002 45099 45107
178. V. Audrito, T. Vaisitti, D. Rossi, D. Gottardi, G. D'Arena, L. Laurenti, and et al. Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network Cancer Res. 71 2011 4473 4483
179. R.H. Houtkooper, E. Pirinen, and J. Auwerx Sirtuins as regulators of metabolism and healthspan Nat. Rev. Mol. Cell Biol. 13 2012 225 238
180. J. Yoshino, K.F. Mills, M.J. Yoon, and S. Imai Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice Cell Metab. 14 2011 528 536
181. R.H. Houtkooper, and J. Auwerx Exploring the therapeutic space around NAD+ J. Cell Biol. 199 2012 205 209
182. Z. Benyó, A. Gille, J. Kero, M. Csiky, M.C. Suchánková, R.M. Nüsing, and et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing J. Clin. Invest. 115 2005 3634 3640
183. C. Cantó, R.H. Houtkooper, E. Pirinen, D.Y. Youn, M.H. Oosterveer, Y. Cen, and et al. The NAD+ precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity Cell Metab. 15 2012 838 847
184. B. Gong, Y. Pan, P. Vempati, W. Zhao, L. Knable, L. Ho, and et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-γ coactivator 1α regulated β-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models Neurobiol. Aging 34 2013 1581 1588
185. N.A. Khan, M. Auranen, I. Paetau, E. Pirinen, L. Euro, S. Forsström, and et al. Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3 EMBO Mol. Med. 6 2014 721 731
186. L. Bracci, G. Schiavoni, A. Sistigu, and F. Belardelli Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer Cell Death Differ. 21 2014 15 25
187. W.J. Kaiser, J.W. Upton, A.B. Long, D. Livingston-Rosanoff, L.P. Daley-Bauer, R. Hakem, and et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice Nature 471 2011 368 372
188. T.A. Prolla, and J.M. Denu NAD+ deficiency in age-related mitochondrial dysfunction Cell Metab. 19 2014 178 180
189. M. Cea, A. Cagnetta, M. Fulciniti, Y.-T. Tai, T. Hideshima, D. Chauhan, and et al. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition Blood 120 2012 3519 3529
190. S. Okumura, T. Sasaki, Y. Minami, and Y. Ohsaki Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation J. Thorac. Oncol. 7 2012 49 56
191. M. Munk Jensen, K.D. Erichsen, C.B. Johnbeck, F. Björkling, J. Madsen, M. Bzorek, and et al. [18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts PLoS One 8 2013 e53410
192. S.F. Zerp, C. Vens, B. Floot, M. Verheij, T. van, and B. riest NAD+ depletion by APO866 in combination with radiation in a prostate cancer model, results from an in vitro and in vivo study Radiother. Oncol. 110 2014 348 354
193. C. Schou, E.R. Ottosen, H.J. Petersen, F. Björkling, S. Latini, P.V. Hjarnaa, and et al. Novel cyanoguanidines with potent oral antitumour activity Bioorg. Med. Chem. Lett. 7 1997 3095 3100
194. P.J. Vig Hjarnaa, E. Jonsson, S. Latini, S. Dhar, R. Larsson, E. Bramm, and et al. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo Cancer Res. 59 1999 5751 5757
195. E. Jonsson, L.E. Friberg, M.O. Karlsson, H. Bashir, S. assan, A. Freijs, K. Hansen, and et al. Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats Cancer Chemother. Pharmacol. 46 2000 493 500
196. P. Martinsson, G. Liminga, S. Dhar, de, T. la, M. orre, A. Lukinius, E. Jonsson, and et al. Temporal effects of the novel antitumour pyridyl cyanoguanidine (CHS 828) on human lymphoma cells Eur. J. Cancer 37 2001 260 267
197. A. Svensson CHS 828 inhibits neuroblastoma growth in mice alone and in combination with antiangiogenic drugs Pediatr. Res. 51 2002 607 611
198. V. Johanson, Y. Arvidsson, L. Kölby, P. Bernhardt, C. Swärd, O. Nilsson, and et al. Antitumoural effects of the pyridyl cyanoguanidine CHS 828 on three different types of neuroendocrine tumours xenografted to nude mice Neuroendocrinology 82 2005 171 176
199. L.E. Friberg, S.B. Hassan, E. Lindhagen, R. Larsson, and M.O. Karlsson Pharmacokinetic-pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model Eur. J. Pharm. Sci. 25 2005 163 173
200. H. Kato, E. Ito, W. Shi, N.M. Alajez, S. Yue, C. Lee, and et al. Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma Clin. Cancer Res. 16 2010 898 911